No, read the poster, only the one CR from the early MAST cohorts.
These results are extremely disappointing, and we're unlikely to get any sort of accelerated approval for this indication any time soon. Much more trial work to be done on various doses and combinations.
Given such a promising start with the CR, I was hoping to see CF33 nail this indication.
Maybe low dose is better? Get tumour killing done before the body launches an antiviral response?
Now we know why they haven't been keeping us updated on this open label trial. Probably desperately been holding out for another CR to announce. But it hasn't eventuated.
Looks like two expansion cohorts both focused on chiolangiocarcinoma, which may mean that MAST hasn't generated any other really promising lead indication, other than a particular type of bladder cancer.
CF33 - possibly clinically useful and effective, but not the tumour killing machine it has sometimes been presented as.
IMU Price at posting:
2.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)